Literature DB >> 11164108

In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.

K Asosingh1, H De Raeve, P Croucher, E Goes, I Van Riet, B Van Camp, K Vanderkerken.   

Abstract

Multiple myeloma, a plasma cell malignancy, is predominantly localized in the bone marrow. These tumoral cells display a heterogeneous expression of CD45. It is, however, unclear which subpopulation is responsible for the homing and outgrowth of the myeloma cells. In this work, we investigated the in vivo homing, proliferation, and differentiation of both CD45+ and CD45- cells in two murine myeloma models.5T2MM and 5T33MM in vivo lines of murine multiple myeloma were used. CD45 and IGF-I receptor expression was analyzed by FACS. Proliferative capacity was assessed by in vivo bromodeoxyuridine incorporation. 5TMM cells were separated into CD45+ and CD45- fractions by MACS. Initial homing was investigated in vivo by tracing of radioactively labeled cells. Myeloma cells were detected by FACS and histology. Osteolytic lesions were analyzed by radiography. Both CD45+ and CD45- 5TMM cells were able to home to the bone marrow, although the migration of the latter subset was lower, which was related to a low IGF-I receptor expression. Recipients of both fractions developed myeloma as evidenced by the presence of serum paraprotein, osteolytic lesions, and bone marrow infiltration by myeloma cells. The tumor load in the recipients of CD45- cells was higher than the CD45+ cells, which could be explained by a lower proliferation rate of the latter population. While the separated cells before injection had a homogenous expression of CD45, cells isolated from the bone marrow of these terminally diseased mice had a heterogeneous expression pattern, indicating an in vivo differentiation pattern of CD45- to CD45+ cells and vice versa. We conclude that both CD45+ and CD45- 5TMM subpopulations contain clonogenic myeloma cells with bone marrow homing and proliferative capacity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11164108     DOI: 10.1016/s0301-472x(00)00625-1

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.

Authors:  Shmuel Yaccoby
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

2.  DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.

Authors:  Duncan R Hewett; Kate Vandyke; David M Lawrence; Natasha Friend; Jacqueline E Noll; Joel M Geoghegan; Peter I Croucher; Andrew C W Zannettino
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

Review 3.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

4.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

5.  The effects of forodesine in murine and human multiple myeloma cells.

Authors:  Liesbeth Bieghs; Jo Caers; Elke De Bruyne; Els Van Valckenborgh; Fiona Higginbotham; Karin Vanderkerken; Eline Menu
Journal:  Adv Hematol       Date:  2010-10-19

6.  Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Authors:  Kewal Asosingh; Eline Menu; Els Van Valckenborgh; Isabelle Vande Broek; Ivan Van Riet; Ben Van Camp; Karin Vanderkerken
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.

Authors:  Yunjing Zeng; Li Gao; Xiaoqing Luo; Yan Chen; Mustafa H Kabeer; Xuelian Chen; Andres Stucky; William G Loudon; Shengwen C Li; Xi Zhang; Jiang F Zhong
Journal:  Mol Oncol       Date:  2018-05-12       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.